ReviewCurrent oncology reports2021
Desmoid Fibromatosis: Management in an Era of Increasing Options.
Review in Current oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Desmoid Tumor of the Porta Hepatis: A Rare Location With Unusual Clinical Presentation.Case reports in hepatology · 2026Article
- Systematic review of transarterial chemoembolization for desmoid tumors: a promising locoregional treatment for challenging tumor.Discover oncology · 2025Review
- Transarterial doxorubicin-eluting beads embolization for the treatment of desmoid fibromatosis in the pubic region.Radiology case reports · 2024Article
- Real-life experience with sorafenib for advanced and refractory desmoid-type fibromatosis.Acta oncologica (Stockholm, Sweden) · 2024Article
- Article
- Current Treatment Concepts for Extra-Abdominal Desmoid-Type Fibromatosis: A Narrative Review.Cancers · 2024Review
- Efficacy and safety of different thermal ablative therapies for desmoid-type fibromatosis: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2023Article
- Papillary thyroid carcinoma with desmoid fibromatosis: a case report and review of literature.Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2023Review
- Desmoid Tumors: A Comprehensive Review.Advances in therapy · 2023Review
- Challenging Diagnostic Dilemma: Mesenteric Desmoid Tumor Masquerading as Perforated Peritonitis.Cureus · 2023Article
- Article
- Establishment and characterization of NCC-DSM1-C1: a novel cell line derived from a patient with desmoid fibromatosis.Human cell · 2023Article
- Unusual and rare cause of abdominal pain: abdominal desmoid fibromatosis masquerading as a postoperative haematoma.BMJ case reports · 2022Article
- Risk factors for recurrence of abdominal aggressive fibromatosis after radical surgery: An 8-year observational study from a chinese high-volume sarcoma center.Journal of clinical and translational research · 2022Article
- Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition.NPJ precision oncology · 2022Review
- The Role of Pharmacotherapeutic Agents in Children with Desmoid Tumors.Paediatric drugs · 2022Review
- Misdiagnosed desmoid fibromatosis of the chest wall presenting in emergency like as recurrence of post-traumatic hematoma: A case report and review of the literature.International journal of surgery case reports · 2022Article
- Circulating Tumor Cells in Desmoid Tumors: New Perspectives.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewDesmoid fibromatosis (DF) is a locally aggressive clonal neoplasm with locally aggressive behavior and no metastatic potential. Historical treatment of DF has consisted primarily of up-front surgery when feasible. In recent years, recognition that DF can spontaneously stabilize or involute has allowed for many patients to be managed with watchful waiting rather than intervention. This review is intended to review recent developments in the treatment of DF. RECENT
findingsRecent studies have demonstrated prospectively that patients with DF often have improvement in their lesions without intervention, enabling an initial period of surveillance as a standard option for patients with mild symptoms. Given the lengthening list of effective systemic treatments, including sorafenib, pazopanib, and experimental agents, there has been a less reliance on local therapies for those patients who require treatment. For patients with DF that require treatment, there is a growing list of options that includes radiation therapy (RT), percutaneous ablation, and a growing list of systemic agents with favorable toxicity profiles.
Indexed as
Identifiers
33719012What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.